The Effect of Information Support Program on Self-efficacy of Prostate Cancer Patients During Hormonal Therapy

Condition:   Information Support Intervention:   Other: information support program Sponsor:   Fudan University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

For men with advanced prostate cancer, a new hormone therapy pill works better than standard injections -- and carries a much lower risk of heart attack or stroke.
Source: WebMD Health - Category: Consumer Health News Source Type: news
FRIDAY, May 29, 2020 -- For men with advanced prostate cancer, a new hormone therapy pill works better than standard injections -- and carries a much lower risk of heart attack or stroke, a clinical trial has found. The drug, called relugolix, is...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
In conclusion, we suggest that Mo-MDSC should be considered as a potential therapy target in the course of prostate cancer treatment to enhance its anti-tumor effectiveness. PMID: 32429654 [PubMed - in process]
Source: Polish Journal of Pathology - Category: Pathology Tags: Pol J Pathol Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Stereotactic body radiotherapy (SBRT) with the delayed option of androgen deprivation therapy (ADT) is the current treatment paradigm in men relapsed with oligometastatic prostate cancer based on the outcome of a phase II randomised controlled study. The immediate (concomitant) use of ADT in this clinical setting potentially augments the efficacy of SBRT by improving systemic disease control. The aim of this study was to compare the clinical outcomes of these two treatment strategies.
Source: Clinical Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® i...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
AbstractStandard therapy for metastatic small cell carcinoma of the prostate (SCCP) remains undefined. We have effectively treated relapsed SCCP with amrubicin. A 72-year-old patient, diagnosed with T4N1M0 prostate cancer, started hormonal therapy in May 2012, elsewhere, and his prostate-specific antigen levels remained low. However, pulmonary and hepatic metastases occurred; high neuron-specific enolase levels suggested SCCP, which was confirmed by repeated biopsy at our institution. In October 2016, chemotherapy with irinotecan and cisplatin was initiated for metastases to the lung, liver, and left pelvic lymph nodes, an...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
Progress in understanding how the prostate regenerates after hormone therapy may one day lead to improved therapies for prostate cancer.
Source: NIH Research Matters - Category: Research Source Type: news
Accumulating evidence suggests androgen receptor splice variant 7 (AR-V7) may be associated with the prognosis of castration-resistant prostate cancer (CRPC) received novel hormonal therapy while its character...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Treatments for prostate cancer are always evolving, and now research is pointing to new ways of treating a cancer that has just begun to spread, or metastasize, after initial surgery or radiation. Doctors usually give hormonal therapies in these cases to block testosterone, which is a hormone that makes the cancer grow faster. But newer evidence shows that treating the metastatic tumors directly with radiation can produce better results. In March, researchers published the latest study that supports this approach. Based at Johns Hopkins University School of Medicine in Baltimore, the team used a method for delivering power...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Living With Prostate Cancer Prostate Knowledge Treatments HPK Source Type: blogs
More News: Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | Prostate Cancer | Research